Objective: In addition to N-methyl-d-aspartate receptor antagonism, ketamine produces
opioid system activation. The objective of this study was to determine whether opioid …

Background Antidepressant response to a single subanesthetic dose infusion of the
glutamatergic modulator ketamine is transient in most depressed patients; however, a …

Rationale Depressive episodes are the leading cause of mental health-related hospital
admissions in Australia, and 44% of those admitted have a previous history of …

Background Ketamine rapidly improves depressive symptoms in patients with treatment-
resistant major depressive disorder (MDD) who do not respond to multiple standard …

The N-methyl-D-aspartate glutamate receptor antagonist ketamine has demonstrated rapid
antidepressant effects in treatment-resistant depression (TRD). However, evaluation of …

The N-methyl-d-aspartate (NMDA) receptor antagonist ketamine is associated with rapid but
transient antidepressant effects in patients with treatment resistant unipolar depression …

Objectives Ketamine has shown rapid antidepressant effects in depressed patients.
However, the antidepressant and antisuicidal effects of repeated ketamine infusions in …

Background Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are
both currently used for treatment-resistant major depression, but the comparative …

Repeated administration of subanesthetic intravenous ketamine may prolong the rapid
decrease in suicidal ideation (SI) elicited by single infusions. The purpose of this secondary …

Approximately one-third of patients with major depressive disorder (MDD) do not respond to
existing antidepressants, and those who do generally take weeks to months to achieve a …